- Home
- KRRO vs GLSI Comparison
KRRO vs GLSI Comparison
Compare KRRO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- GLSI
- Stock Information
- Founded
- KRRO 2014
- GLSI 2006
- Country
- KRRO United States
- GLSI United States
- Employees
- KRRO N/A
- GLSI N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- GLSI Health Care
- Exchange
- KRRO Nasdaq
- GLSI Nasdaq
- Market Cap
- KRRO 125.4M
- GLSI 134.6M
- IPO Year
- KRRO 2019
- GLSI 2020
- Fundamental
- Price
- KRRO $15.07
- GLSI $11.75
- Analyst Decision
- KRRO Strong Buy
- GLSI Strong Buy
- Analyst Count
- KRRO 7
- GLSI 1
- Target Price
- KRRO $85.67
- GLSI $39.00
- AVG Volume (30 Days)
- KRRO 122.8K
- GLSI 78.4K
- Earning Date
- KRRO 08-12-2025
- GLSI 08-13-2025
- Dividend Yield
- KRRO N/A
- GLSI N/A
- EPS Growth
- KRRO N/A
- GLSI N/A
- EPS
- KRRO N/A
- GLSI N/A
- Revenue
- KRRO $4,821,000.00
- GLSI N/A
- Revenue This Year
- KRRO $65.08
- GLSI N/A
- Revenue Next Year
- KRRO N/A
- GLSI N/A
- P/E Ratio
- KRRO N/A
- GLSI N/A
- Revenue Growth
- KRRO N/A
- GLSI N/A
- 52 Week Low
- KRRO $10.29
- GLSI $8.06
- 52 Week High
- KRRO $98.00
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- KRRO 48.70
- GLSI 53.88
- Support Level
- KRRO $13.34
- GLSI $11.16
- Resistance Level
- KRRO $16.77
- GLSI $11.73
- Average True Range (ATR)
- KRRO 1.46
- GLSI 0.74
- MACD
- KRRO -0.05
- GLSI -0.08
- Stochastic Oscillator
- KRRO 28.68
- GLSI 42.91
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.